PRESS RELEASE published on 01/24/2025 at 07:00, 1 year 7 months ago BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports preliminary full-year 2024 results with a net profit of CHF 76 mn, proposing a dividend of CHF 1.80 per share at the AGM on March 19, 2025, focusing on shareholder returns and biotech sector growth Preliminary Results Dividend Proposal Biotech Sector Shareholder Returns BB Biotech
PRESS RELEASE published on 01/24/2025 at 07:00, 1 year 7 months ago EQS-Adhoc: BB Biotech AG closes the 2024 fiscal year with a profit BB Biotech AG closes the 2024 fiscal year with a profit of approximately CHF 76 million, reflecting share price development. Preliminary unaudited figures show a significant improvement from the previous year Investment Company Preliminary Figures BB Biotech AG Profit 2024 Fiscal Year
BRIEF published on 01/22/2025 at 14:36, 1 year 7 months ago Edison Highlights BB Biotech's Portfolio Boost Acquisition Net Asset Value Investment Biotech Sector BB Biotech
BRIEF published on 01/22/2025 at 14:36, 1 year 7 months ago Edison souligne l'augmentation du portefeuille de BB Biotech Acquisition Investissement Secteur Biotechnologique Valeur Nette D'inventaire Biotechnologie BB
PRESS RELEASE published on 01/22/2025 at 14:31, 1 year 7 months ago Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION) highlighting recent positive developments and implications for the biotech sector. Johnson & Johnson's acquisition of Intra-Cellular Therapies at a premium has boosted BB Biotech's net asset value Acquisition Edison Biotech Sector BB Biotech Johnson & Johnson
BRIEF published on 10/25/2024 at 07:05, 1 year 10 months ago BB Biotech AG Releases Interim Report with Positive Net Profit Investment Net Profit Biotech Sector Interim Report BB Biotech
BRIEF published on 10/25/2024 at 07:05, 1 year 10 months ago BB Biotech AG publie un rapport intermédiaire avec un bénéfice net positif Investissement Bénéfice Net Rapport Intérimaire Secteur Biotechnologique Biotechnologie BB
BRIEF published on 10/25/2024 at 07:05, 1 year 10 months ago BB Biotech: Strategic Portfolio Reallocation Amid Volatile Markets Financial Results Investment Strategy Biotech Sector BB Biotech Portfolio Reallocation
BRIEF published on 10/25/2024 at 07:05, 1 year 10 months ago BB Biotech : Réallocation stratégique du portefeuille dans un contexte de marchés volatils Résultats Financiers Stratégie D'investissement Secteur Biotechnologique Biotechnologie BB Réaffectation Du Portefeuille
PRESS RELEASE published on 10/25/2024 at 07:00, 1 year 10 months ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first nine months of 2024, showing a net profit and strategic investment details Investment Company Net Profit BB Biotech AG Interim Report Stocks
Published on 09/12/2026 at 02:35, 11 hours 49 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 24 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 19 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 59 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 24 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 54 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 9 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 14 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 40 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 9 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
